Lexicon Pharmaceuticals

At the H.C. Wainwright conference, Lexicon Pharmaceuticals presented a focused cardiometabolic strategy and placed sotagliflozin at the center of its near-term plans. The company expects top-line data from the Phase III SONATA-HCM study in Q1 2027 and is planning a possible resubmission to the FDA for type 1 diabetes in Q4 2026. Lexicon is expanding pre-commercial activities, reported milestone payments from Novo Nordisk for the obesity program LX9851, and emphasized operational discipline and support from partnerships with Novo Nordisk and Viatris. » More on de.investing.com

At the Leerink conference, Lexicon Pharmaceuticals set its strategic focus on cardiometabolic diseases and chronic pain, prioritizing late‑stage programs. The company plans a resubmission of the NDA for Zynquista in type 1 diabetes, the SONATA Phase‑3 study of sotagliflozin in HCM will complete recruitment by midyear, and a Phase‑3 design for pilavapadin in DPNP has been agreed with positive FDA feedback. The partnership with Novo Nordisk for LX9851 has hit milestones (USD 10 million) with further payments possible, while regulatory approval risks and competitive pressure remain key challenges. » More on de.investing.com

Lexicon Pharmaceuticals reported Q4 2025 EPS of -$0.04 (expected -$0.07) and revenue of $5.5 million versus projected $3.92 million. The company sharply cut R&D and SG&A expenses and significantly improved its net loss year over year. Despite the stronger metrics, the stock fell about 4.3% in premarket trading. For 2026, Lexicon expects total operating costs of $100–$110 million and is focusing investments on its cardiometabolic platform, including sotagliflozin and a resubmission for Zynquista. » More on de.investing.com